摘要
目的探讨曲伏前列素滴眼液治疗原发性开角型青光眼的疗效。方法选择医院2016年1月至2017年1月收治的原发性开角型青光眼患者98例,按随机数字表法分为对照组和观察组,各49例。对照组采用噻吗洛尔滴眼液治疗,早晚各给药1次,每次1滴;观察组采用曲伏前列素滴眼液治疗,晚上给药1次,每次1滴。均治疗8周。结果观察组治疗总有效率为95.92%,明显高于对照组的79.59%(P<0.05)。对照组心动过缓、眼部刺痛各3例,眼表烧灼痛、一过性头晕各2例,总发生率为20.41%;观察组仅有2例结膜充血,发生率为4.08%,明显低于对照组的20.41%(P<0.05);观察组患者眼压恢复正常时间、自觉症状消失时间均明显短于对照组(P<0.05);治疗前和治疗2,4周两组眼压水平无显著差异(P>0.05),治疗8周观察组眼压水平显著低于对照组(P<0.05)。结论曲伏前列素滴眼液治疗原发性开角型青光眼疗效确切,可有效降低眼压,改善临床症状,缩短疗程,不良反应少,安全性较高。
Objective To investigate the clinical effect of Travoprost Eye Drops for treating primary open-angle glaucoma. Methods Totally98 patients with primary open-angle glaucoma from January 2016 to January 2017 in our hospital were divided into the control group and the observation group according to the random number table method. The control group was given Timolol Eye Drops,1 time each morning and evening, 1 drop each time. The observation group was given Travoprost Eye Drops, 1 time in the evening, 1 drop each time. Results The total effective rate of the observation group was 95. 92%,which was significantly higher than 79. 59% of the control group（ P〈0. 05）. The control group had 3 cases of bradyarrhythmia,2 cases of stabbing pain on eyes,3 cases of burning pain on the ocular surface,2 cases of transient dizziness,the incidence rate was 20. 41%,only 2 cases of conjunctival congestion in the observation group,the incidence rate was 4. 08%,which was significantly lower than 20. 41% of the control group（ P〈0. 05）. The time of recovery to normal pressure and the disappearance time of conscious symptoms of the observation group were significantly shorter than those of the control group（ P〈0. 05）. There was no significant difference in intraocular pressure（ IOP） level between the two groups before treatment,2 weeks after treatment and 4 weeks after treatment（ P〉0. 05）,after 8 weeks of treatment,the IOP level of the observation group was significantly lower than that of the control group（ P〈0. 05）. Conclusion Travoprost Eye Drops is effective in the treatment of primary open-angle glaucoma, it can effectively reduce IOP level, improve clinical symptoms, shorten the course of treatment with less adverse reactions and high safety.
出处
《中国药业》
CAS
2017年第21期66-68,共3页
China Pharmaceuticals
作者简介
姚鹏（1982-）,男,博士研究生,主治医师,研究方向为眼科、青光眼白内障眼底病,（电子信箱）249635160@qq.com.
通讯作者：杨惠婷（1982-）,女,博士研究生,主治医师,研究方向为眼科,（电子信箱）82538732@qq.com.
